- LOGIN
- MemberShip
- 2025-12-23 12:43:41
- Policy
- 342 items unable for supply voluntarily withdraw listing
- by Lee, Hye-Kyung Nov 02, 2021 05:53am
- In just one year since the pharmaceutical negotiation system that had been only used for new drugs and usage volume negotiations was expanded to include generics, etc., 342 items that cannot be immediately supplied were deleted from the reimbursement list by ‘voluntary withdrawal.’ The National Health Insurance Service announced that it had completed negotiations for 1,508 items since introducing the negotiation system on generics, etc. Specifically, 912 items were newly listed, 37 items made ex-officio adjustments, 79 items made voluntary withdrawals, and 480 items received reevaluation on their premiums. In particular, ex-officio adjustments were made for 25 original items, 2 shortage prevention items, 1 prior price cut item, and 9 labeling change items. The NHIS also stressed that the negotiations enabled companies to voluntarily withdraw reimbursement listing applications for 342 items that could not be supplied immediately after listing, initially blocking the ‘blind listing’ of drugs under the positive list system. On the 1st, the NHIS distributed the reference material on the negotiation system for generics, etc., and made the self-evaluation that the system entered the ‘stabilization phase’ in one year since its implementation. As the negotiation system for generics is a systemized measure for the supply and quality management of pharmaceuticals, the authorities also expressed gratitude to the pharmaceutical industry that participated in the negotiations and expressed that the performance was 'the result of win-win cooperation.' NHIS admitted that “There were some industry concerns that the negotiations for generics, etc. could delay reimbursement listing, and whether the system could block blind listing of drugs. However, we were able to stably implement the negotiation system without delaying listing by newly establishing a Pharmaceutical Pricing Management Office, increasing negotiating personnel, and introducing the prior consultation system to ensure a sufficient amount of period for negotiations.” NHIS added, “The new payer model that embraces both public safety and patient protection shifted the paradigm. However, the new negotiation system has been increasing the industry’s administrative burden, and the No.1 inconvenience pointed out by the industry is the increased burden of submitting documents on manufacturing and import performance." Therefore, to promptly address the inconveniences experienced by the pharmaceutical industry, the NHIS, and the MFDS are linking the information between the ministries to resolve the overlapping manufacturing and import data submissions and reduce the administrative burden within the first quarter of next year. An NHIS official said, “We will continue to work with pharmaceutical industry officials to ensure stable supply and quality management of pharmaceuticals. We will make diverse efforts to improve the system and simplify the administrative process to provide cost-effective, high-quality, and safe generic drugs to the public,”
- Policy
- Is the first generic release of the ADHD tx Concerta?
- by Lee, Tak-Sun Nov 02, 2021 05:53am
- Alvogen Korea has begun to develop a generic development of the ADHD treatment Concerta OROS (Methylphenidate, Janssen Korea). Since there is currently no generic for Concerta in Korea, it is expected to be the first generc if approved. As of the 28th, the MFDS approved AK-D309 54mg's biological equivalence test plan. In this test, Alvogen will conduct a bioequivalence test evaluation with control group on 58 healthy adults. The target disease is ADHD. It is estimated to be Concerta OROS 54mg. This is because there is only 54 mg formulation for Concerta OROS for ADHD treatment. Concerta OROS 54mg is a leading product in the ADHD treatment market. Sales amounted to 15.4 billion won based on IQVIA last year. The reason why this product is leading the market is that it is taken once a day. Bisphentin Controlled-Release Cap of Methylphenidate HCl, which was approved in 2015, is also a capsule formulation different from Concerta OROS. As a competitive product, there was also Whan In's Metadate CDER capsule, which was taken once a day, but the supply was suspended from August 2019 due to the termination of the original developer's contract, and the product license was withdrawn in May. Analysts say that the competitiveness of Concerta OROS has improved further due to the suspension of supply of Metadate CDER. Concerta's patent was also terminated on May 27, 2019. Generics can enter the market without any burden. However, despite these advantages, there have been no generic so far. Because of the ER formulation, it's hard to develop generics. This is because generic competitiveness was weak due to the nature of CNS treatments. Whan In has started to develop products as an alternative to Metadate CD ER, but it is said to have been suspended now. If Alvogen succeeds in developing generic, it will be the first generic in Korea. Alvogen is focusing on expanding related markets by introducing domestic copyrights for CNS treatments such as Novartis' Stalevo and Comtan last year. Therefore, the launch of the ADHD treatment bioequivalence test is also interpreted as a strategy as part of market expansion. Attention is focusing on whether Alvogen will emerge as a dark horse in the CNS treatment market as the first generic.
- Policy
- Generics for Jardiance have obtained generic for exclusivity
- by Lee, Tak-Sun Nov 02, 2021 05:53am
- Jardiance, a diabetes tx imported and sold by Beringer Ingelheim Korea Generics of SGLT-2 inhibitory diabetes treatment Jardiance (Empagliflozin, Beringer Ingelheim, Korea) have obtained a number of generic for exclusivity. The number of target items alone amounts to 93. Most of the licensed products have won generic for exclusivity. It will be applied for nine months from October 24, 2025, the date of sale. According to the MFDS on the 29th, 93 generics for Jardiance acquired generic for exclusivity as of the 27th. The effective date is from October 24, 2025, when Jardiance's substance license ends. The generic for exclusivity is granted to the first applicant for permission after the patent challenge is successful challenge. It can be said that all 93 companies met this standard. First of all, the patent challenge filed a passive rights scope confirmation trial with Jardiance's decisive patent (scheduled to expire on December 14, 2026) in January 2018 and received a partial trial in May 2019. As Beringer Ingelheim followed the trial, the trial was confirmed as it was. Generics also applied for permission in time for August 11, 2020, when Jardiance's PMS ends, meeting the criteria for applying for initial permission along with the success of patent avoidance. Starting with Dongkoo Pharmaceutical in February, it began to obtain product permits. The acquisition date of generic for exclusivity is eight months later than this. In response, an official from the MFDS explained the late acquisition of generic for exclusivity, saying, "The fact that the start date of generic for exclusivity is from 2025 also contributed to the review." Analysts say that the market monopoly, which can be said to be the biggest effect of generic for exclusivity, has been overshadowed by the fact that generic for exclusivity items reach more than 100. However, as the Act on the Restriction of Consigned Production Items has been enforced since July, it is expected that dozens of items will not be able to obtain preferential rights at the same time in the future. Meanwhile, Jardiance is a large diabetes treatment that recorded 35.4 billion won in outpatient prescriptions (based on UBIST) last year.
- Policy
- Redundancies in CDRD and PBAC roles in continuous dispute
- by Lee, Hye-Kyung Nov 01, 2021 05:56am
- [News follow-up from a friendly reporter] The functional redundancies in the Cancer Disease Review Committee (CDRC) and Pharmaceutical Benefit Appraisal Committee (PBAC) arose as an issue at the NA Health and Welfare Committee audit recently. At the audit, the National Assembly Health and Welfare Committee member Sun-woo Kang of the Democratic Party of Korea had pointed out that a long-term delay has occurred in discussions on expanding reimbursement for a new anti-cancer drug due to the redundant functions of the two committees. The new anti-cancer drug that Kang referred to was MSD Korea’s ‘Keytruda (pembrolizumab).’ ‘Keytruda is an immuno-oncology drug that was first approved reimbursement for NSCLC patients with ‘Opdivo (nivolumab)’ on August 21st, 2017. The issue arose with the reimbursement for Keytruda in first-line in lung cancer delayed for 4 years. According to the data disclosed by Kang, MSD Korea applied to extend reimbursement of Keytruda to first-line NSCLC in September 2017, but the agenda finally passed the CDRC in July 2021. Why the delay? The CDRC had delayed making the decision for 4 years due to concern over its fiscal sharing plan despite having no disagreement over the drug’s clinical usefulness. New anti-cancer drugs require CDRC review for setting reimbursement standards, but the fiscal sharing discussions that should be discussed at the PBAC were also conducted at the CDRC level. The CDRC has less than half the personnel of PBAC, and remarks of Ministry of Health and Welfare officials at public hearings or debates indicate that they expect CDRC to make decisions based on objectivity rather than expertise. In other words, objective reimbursement standards are set at the CDRC level without input from the pharmaceutical company. But Keytruda’s review was put on hold for 4 years over its ‘fiscal sharing’ at CDRC, not its reimbursement standards. That was why the drug was mentioned as an example at the NA audit. What about HIRA? To what extent does the HIRA stipulate the scope of the work for CDRC? The scope of work for CDRC and PBAC are stipulated in the ‘Regulations on the Criteria for NHI Insurance Benefits.’ Article 5-2 of the regulation stipulates that ‘HIRA should organize a CDRC to deliberate the methods and standards for applying insurance benefit to medicines prescribed and administered to severe disease patients.’ The members of the committee should be comprised of 45 or fewer members with extensive experience and profound knowledge in the field of public health.’ In other words, under the regulations, the CDRC deliberates the standards and methods for drugs used for patients with rare, severe diseases or cancer. HIRA sees that the committee may assess a drug’s medical feasibility, alternative drugs and treatment cost, fiscal impact, etc. to deliberate its reimbursement standards. This was included in the written QA that was submitted after Kang’s NA audit, but the contents of the deliberation for setting the reimbursement standards could not be found. However, DREC’s role is clearly stated in the regulations. Article 11-2 of the regulation is the basis for DREC, and it reviews insurance benefits of drugs that applied for assessment under Article 10-2(3). DREC has subcommittees for drug benefit standards, economic evaluation, RSA, fiscal impact assessment, herbal medicine, post-marketing evaluation, etc. The manpower pool for DREC is 102, and the members evaluate whether new drugs are eligible for medical care insurance benefits, reimbursement standards, and the price cap for drugs based on calculation standards. The stipulated standards show that the functions of CDRC and DREC need not overlap. HIRA explained that a delay in deliberation had occurred at the CDRC level due to the fiscal burden that may arise in NHI finances due to the high price of new anticancer drugs. However, financial sharing is an agenda that needs to be reviewed by DREC or the NHI that has fiscal power, not the CDRC. Therefore the question that lies is whether the 45 non-expert members of the CDRC had the authority to neglect the patients’ 4 years’ worth of time over the fiscal sharing plan.
- Policy
- HIRA clarifies ‘Opdivo·Keytruda·Tecentriq’ eligibility
- by Lee, Hye-Kyung Nov 01, 2021 05:56am
- The 'Stage ⅢB or higher’ phrase was added to the subjects eligible for reimbursement of ‘Opdivo (nivolumab),’ ‘Keytruda (pembrolizumab),’ and ‘Tecentriq (atezolizumab)’ in NSCLC. The Health Insurance Review and Assessment Service announced that it will implement the ‘Amendment to the Notice on Drugs Prescribed and Administered to Cancer Patients' which will take effect from November 1. The amendment was made to address the confusion that arose regarding the eligibility of reimbursement after the cancer stage criteria were deleted in subjects for immunotherapy as second-line or subsequent lines of palliative therapy on May 1st. HIRA added the 'Stage ⅢB or higher’ to ‘patients who have previous platinum-based chemotherapy experience with positive PD-L1 expression (expression rate ≧ 10%)’ in the criteria for the administration of Opdivo, Keytruda, and Tecentriq as second-line or higher therapy in NSCLC. Also, the G-CSF injection, ‘Rolontis Pre-filled Syringe (eflapegrastim)’ was included in the announced amendment. Rolontis Pre-filled Syringe was approved to reduce the incidence of severe neutropenia in patients that receive cytotoxic chemotherapy for solid cancers and malignant lymphoma. After reviewing the reimbursement standards, HIRA decided that Rolontis was necessary for treatment and set a standard for the drug after the drug demonstrated non-inferiority to the currently reimbursed eflapegrastim in the mean duration of severe neutropenia through a Phase III clinical trial in cycle 1.
- Policy
- Concerns about the introduction of the Reference Price
- by Kim, Jung-Ju Nov 01, 2021 05:55am
- The government expressed concern over the National Assembly's proposal to review the introduction of the Reference Pricing System. Although they sympathize with the need for rational drug price management, side effects such as an increase in the patient's economic burden are predicted from the reference price system itself. Regarding price policies, such as proposals for mandatory general administration, it said that the pros and cons of the pharmaceutical industry and conflicts will be reviewed through collecting various opinions because social consensus is important. The MOHW recently submitted a written response to such issues related to drug price policies proposed and inquired by the Health and Welfare Committee during the last parliamentary audit. Through written inquiries, lawmakers belonging to the Welfare Committee asked about generic drug price policies such as discussing the reference price system to normalize the generic drug market and reduce health insurance finances. The MOHW agreed on the need for drug price management to reasonably manage health insurance drug costs and create a cost-effective generic use environment. In fact, after the Valsartan crisis in 2018, the government has implemented a generic drug price reorganization since July last year to prevent competition for generic turmoil. However, the government was virtually negative regarding the Reference Pricing System. The MOHW explained, "The Reference Pricing System can contribute to reducing health insurance finances, but it is likely to bring about significant changes in the current drug price system and increase the economic burden on patients." The government said, "It is necessary to refer to overseas cases and carefully review them through collecting social opinions." In the case of generic substitution, social consensus is needed in consideration of the principle of division of medicine established in 2000. Currently, one out of every two benefit drugs is given incentives for items that can be generalized, but it is negative in the medical community. The MOHW replied, "We will review it by collecting opinions from related ministries, related organizations, and experts." The Welfare Committee also inquired about the necessity of establishing an expensive drug to prevent it from being recklessly prescribed. In response, the government explained, for example, that in the case of Spinraza, the HIRA is operating a pre-approval system to prevent disputes, and said, "We will consider various drug management measures considering individual drug characteristics of individual drugs."
- Policy
- 'Symbenda' withdraws from Korean market 3 years after reimb.
- by Lee, Tak-Sun Oct 29, 2021 05:54am
- A blood cancer drug that took 7 years from approval to reimbursement is being removed from the market only 3 years since starting its sale in earnest. The company that sells the product has pointed to the termination of their agreement as to the cause of its market withdrawal, however, the analysis is that profitability has declined due to drug price cuts following the introduction of generic drugs earlier this year. According to the Ministry of Food and Drug Safety, Eisai Korea withdrew its license for ‘Symbenda inj. (bendamustine hcl.)’ on the 27th. The withdrawal comes after 10 years since its approval in May 2011. The drug is used to treat blood cancers such as lymphoma and chronic lymphatic leukemia. The drug, which was approved 10 years ago, has only been sold in the market for around 3 years. Symbenda was finally approved for reimbursement 7 years after its approval in September 2018, as combination therapy with rituximab. With the reimbursement, a price cap of 283,793 won per 100mg vial was set for the drug. According to IQVIA, the drug sold 2.5 billion won and 2.2 billion won in 2019 and 2020, respectively. Analysts have said that Symbenda’s performance as a new anticancer drug that finally received reimbursement after 7 years was below than expected. Moreover, the drug’s price has been cut in April this year by 30% with the introduction of its generics and set at 198,655 won per 100mg vial. After Boryung Pharmaceutical received the first approval for Symbenda’s generic in November last year, Samyang Holdings and Handok Teva followed into the market with their Symbenda generics. Boryung Pharmaceutical has started selling its first Symbenda generic with reimbursement in April. Eisai Korea, the seller of Symbenda in Korea, notified the MFDS that it would discontinue the supply of Symbenda in April, a month before Handok Teva received the approval for Symbenda’s third generic in May. At the time, Eisai explained, “With the expiry of the partnership agreement that was made between Eisai and the original developer of Symbenda due in October 2021, the company had made the necessary decision to discontinue supply Symbenda in Korea.” The company expected that the 100mg dose will be discontinued in July and the 25mg dose in August. The company added that “Many drugs with the same ingredient that was approved for the same indications are being sold in the market and are available as a replacement for Symbenda. Therefore, the discontinuation of Symbenda’s supply will not affect patients’ treatments. The industry believes that the lower-than-expected performance and the decline in profitability due to the introduction of its generics were what made it difficult for the company to continue on the business in Korea, rather than the two companies'' agreement expiry. With the original’s withdrawal from the Korean market, competition between the three bendamustine generics that are left in the markets and is expected to intensify to compete in filling the original's gap.
- Policy
- KDCA “will monitor development of oral COVID-19 treatments"
- by Lee, Hye-Kyung Oct 29, 2021 05:53am
- The government expressed its determination to introduce a safe treatment with verified efficacy by continuously monitoring the COVID-19 treatment trends, including the US Merck & Co. (MDS)'s oral COVID-19 treatment, 'molnupiravir .' That was the KDCA's response to when NA member Young-seuk Seo of the Democratic Party of Korea asked in via a written inquiry about verifying the efficacy of molnupiravir after the NA audit that was held by the Health and Welfare Committee. Seo asked,” The published results show patients who took placebo or molnupiravir until Day 5 and had no virus detection. Authorities need to consider whether a drug this potent is necessary to increase relief among the public and as well as for disease containment." Regarding Seo’s inquiry, the KDCA said, “We have been reviewing the indications and clinical trial results from various countries." For the approval of an oral COVID-19 treatment the government plans to purchase, the authorities have been comprehensively reviewing various clinical trial results with various measures including the virus detection results, improvement in clinical symptoms, safety assessment, and the drug's approval status in advanced countries such as the United States.” In addition to the publsihed paper, Merck also announced the interim results of its clinical trial on mild-to-moderate patients at high-risk on October 1st. Results showed that 28/385 of the patients who received molnupiravir were hospitalized or died within 29 days of administration compared to the 53/377 in the placebo group. Deaths were reported in 0 patients that were administered molnupiravir and in 8 patients in the placebo group. Also, the drug showed a consistent effect in all mutations, including the gamma, delta, and Mu variants. Based on such results, the company has applied for the Emergency Use Authorization after discussions with the US FDA. KDCA said, “we will continue to monitor COVID-19 treatments and endeavor to introduce safe and verified treatments to Korea."
- Policy
- The government needs to create a sovereign wealth fund
- by Lee, Jeong-Hwan Oct 29, 2021 05:53am
- The National Assembly's Health and Welfare Committee urged both ruling and opposition parties to create tens to hundreds of trillion won worth of sovereign wealth funds to develop blockbuster vaccines and new drugs. As COVID-19 Pandemic has confirmed high demand in the global market for pharmaceutical and bio sectors such as vaccines and new drugs, Korea is also aiming to properly foster global big pharma like Pfizer. On the 27th, Rep. Seo Jung-sook of the People Power Party and Rep. Kang Byeongwon, affiliated with the Welfare Committee, strongly appealed to the MOHW that it is necessary to create a mega-level sovereign wealth fund to foster bio and pharmaceuticals in Korea. According to data submitted by the MOHW to the National Assembly, Korea's national R&D industry budget (2011-2021) totaled 173.7 trillion won, with an annual average of 17.3 trillion won. Among them, the investment budget in the pharmaceutical and bio sectors is 3.2 trillion won, which is being invested in 20,000 projects. In other words, the allocated budget per project is around 160 million won. Korea's budget for supporting the development of COVID-19 vaccines and treatments totaled 120.3 billion won, investing 40.2 billion won in vaccines and 80.1 billion won in treatments. The problem is that Korea's R&D budget in pharmaceutical and bio sectors is far short compared to global cases such as the United States. The United States is investing a total of 8.6 trillion won in vaccines alone. Compared to Korea, it is 70 times higher. The U.S. invested 2.182 trillion won only in Pfizer, a developer of the mRNA coronavirus vaccine and the world's No. 1 Big Pharma. The CEPI is investing 45.4 billion won in SK Bioscience. Lawmakers from the ruling and opposition parties of the Welfare Committee pointed out that it is urgent to create a "developmental sovereign wealth fund" to continue long-term investment while ensuring autonomy in the pharmaceutical and bio sectors. Rep. Seo Jung-sook said, "Korea should foster big pharma like Pfizer." Rep. Seo Jung-sook of the People Power Party pointed out that the government's investment in R&D in the pharmaceutical and bio sectors is too small. It is pointed out that in order to foster pharmaceutical companies that manufacture blockbuster vaccines or treatments that the global market finds first, efforts to innovate Korea's pharmaceutical and bio national budget by actively analyzing overseas cases are needed. In particular, Rep. Seo said that if it is difficult for the government to generate pharmaceutical and bio budgets alone, it should create a sovereign wealth fund in which the government and the private sector work together to have investment power of hundreds of trillion won to hundreds of trillion won. In Korea, the government and the private sector should actively cooperate to create a global big pharma like Pfizer. Representative Seo said, "Pfizer, which developed the COVID-19 vaccine, succeeded in producing PCN itself and secured capital power as it was used in large quantities in World War II and grew into a global pharmaceutical company." She said, "Pharmaceutical and bio cannot grow into a large company like Pfizer without a special opportunity. This is why fostering at the government level is essential, she explained. Rep. Seo said, "The current government is different from blockbuster-class with a distributed investment of 160 million won per project. The U.S. provided KRW 2.182 trillion to Pfizer alone for the COVID-19 vaccine, and the total investment in pharmaceuticals and bio exceeded KRW 8.6 trillion. It is more than 70 times that of 120.3 billion won in Korea, she added. "Domestic vaccines and new drugs are not being developed due to institutional problems." The government is controlled annually and cannot provide large-scale support by using budgets and funds for pharmaceutical and bio investments, it said. "In order to invest large-scale funds in pharmaceutical companies in the long run, we need to actively consider creating development-type sovereign wealth funds." Kang Byungwon said, "Mega funds are urgently needed in Korea" Following the last parliamentary audit, Kang also said it should support phase 3 clinical trials of domestic pharmaceutical companies that started developing blockbuster vaccines and new drugs with "10 trillion megafunds." In particular, Kang said, "Korean pharmaceutical bio companies' technology exports are at the top of the world with 11.6 trillion won, and it is regrettable that they cannot lead to final commercialization." Currently, government-private joint mega funds are essential to overcome the reality that the Korean government only supports R&D support in the pharmaceutical and bio sectors up to Phase 1 and Phase 2 clinical trials. Furthermore, Kang said the government should also take the lead in linking the technology of bio-ventures with the experience of large companies. Rep. Kang said, "The government should actively support the good ideas of pharmaceutical and bio venture companies to lead to the development of final new drugs somehow. The key to the development of new drugs depends on the success of late clinical trials, he said. "We need to create a mega fund in cooperation with the private sector so that the government can support up to phase 3 beyond phase 1 and 2 clinical trials to avoid WTO trade friction." Representative Kang said, "One way is to match and commercialize technology and capital power between bio ventures and large companies, and to support phase 3 clinical trials only for the development of new drugs for public interest purposes." He said, "In order to develop pharmaceutical and bio industries into new industries in the future, now is the most appropriate time when the world is paying attention to vaccines and new drugs due to COVID-19."
- Policy
- Multinational companies have more drugs for PVA
- by Lee, Hye-Kyung Oct 28, 2021 05:58am
- The NHIS made an official position that it cannot accept the criticism that new domestic drugs are being reversely discriminated within the PVA. After the parliamentary audit of the National Assembly's Health and Welfare Committee on the 15th, The NHIS replied, "It cannot be regarded as reverse discrimination in domestic new drugs," when asked about reverse discrimination by People Power Party lawmaker Lee Jong-sung. For this reason, as a result of analyzing drugs applied more than three times in a row since the reorganization of the PVA system in 2014, seven drugs were included in the case of "Type Ka and Na" and six drugs in the case of "Type Da." However, among them, only six types of drugs (type Da) were domestic, and all of the other drugs (type Da) and seven drugs (type Ka and type Na) were from multinational companies. Eight multinational companies had PV negotiations more than three times in a row. In addition, in the case of items that have been cut more than three times, the price has changed due to drug prices and changes in the alternative drug market. The NHIS selected 14,888 drugs as targets for monitoring drug analysis for negotiations on type Da in April this year. Among them, 14,097 drugs from domestic pharmaceutical companies and 791 drugs from multinational pharmaceutical companies were applied, and the final number of drugs subject to negotiation was 55 (0.39%) from domestic pharmaceutical companies and 4 (0.51%) from multinational pharmaceutical companies. Although domestic new drugs seem to be overwhelmingly subject to PVA negotiations, multinational companies are higher when calculating the ratio selected for negotiation. The NHIS explained, "PVA is a system that cuts the upper limit through drug price negotiations between the NHIS and pharmaceutical companies when drug costs increase to a certain level, and the rate of increase in claims affects insurance finances." The NHIS emphasized, "Drugs subject to continuous drug price cuts through PVA continue to affect finances." Rep. Lee Jong-sung also said in the data, "In the case of multinational history, most of them go through PVA in Type Ka and Na, and most of the domestic pharmaceutical companies in Type Da are applied, so it is understood that there is no reverse discrimination overall." Rep. Lee said, "New drugs developed by multinational pharmaceutical companies and entering the domestic market are also subject to PVA measures, but domestic new drugs seem to have been repeatedly cut by PVA." "The government is creating a structure that cuts prices when sales of drugs that have a positive impact on health insurance finances," he said, urging the promotion of motivation for the development of new domestic drugs. The NHIS said, "There was a preferential policy for new domestic drugs, but the related system was changed due to the Korea-U.S. FTA trade dispute," adding, "As soon as the MOHW comes up with research services on preferential measures for domestic pharmaceutical companies, we will review them."
